Objective: To examine the role of indomethacin in neonatal gut injury.
Introduction
Neonatal gut injury as manifested by isolated intestinal perforation (IIP) or necrotizing enterocolitis (NEC) is a serious complication of prematurity. 1, 2 Indomethacin exposure has been implicated as one of the risk factors for neonatal gut-injury in very low birth weight infants. [3] [4] [5] [6] Exposure to indomethacin can occur prenatally [3] [4] [5] and/or postnatally. 6, 7 Indomethacin is used for tocolysis and acts via inhibition of prostaglandin synthetase. 8 Postnatally, indomethacin has been used to effect closure of a patent ductus arteriosus (PDA) 7 or to prevent severe intraventricular hemorrhage in very low birth weight infants. 9, 10 Before 1996, postnatal indomethacin administration at our center was used only to treat PDA, 7 but subsequently its use increased following reports that administration of indomethacin to very low birth weight infants within 6 to 12 h after birth was associated with a reduced rate of severe intraventricular hemorrhage. 9, 10 With increased frequency and early use of indomethacin several reports linking indomethacin exposure to IIP 6, [11] [12] [13] and/or to NEC 6, 14 emerged. Most of these retrospective studies did not carefully differentiate between IIP and NEC nor did they assess the relationship between prenatal indomethacin exposure and neonatal gut injury. Our prospective study examined the effect of both prenatal and postnatal indomethacin exposure on neonatal gut injury among infants with birth weights between 400 and 1200 g. We tested the hypotheses that (1) indomethacin exposure increases the risk of IIP and (2) indomethacin exposure does not increase the risk of NEC. 28 February 2003 we evaluated all infants with gestational age X23 weeks and birth weight between 400 and 1200 g for inclusion in this study. Infants with significant anomalies or with traumatic esophageal or gastric perforation were excluded. Infants with recurrent episodes of NEC or with episodes of NEC after IIP were also excluded. Infants with confirmed NEC (Bell stage II or greater) 15 or confirmed IIP were identified. Diagnosis of IIP or NEC was confirmed by radiographical, surgical and/or pathological findings. A single pediatric radiologist reviewed all abdominal radiographs. At the discretion of attending neonatologist, infants were evaluated for a PDA by echocardiography based on clinical signs such as a characteristic systolic murmur, hyperactive precordium, bounding pulses and/or radiographical findings of pulmonary edema or cardiomegaly. Demographical, surgical and outcome information was collected at weekly or bi-weekly intervals.
Methods

From 1 October 1991 to
In 1996, we adopted the practice of administering indomethacin within 12 h of age in very low birth weight infants. 9, 10 Over the study period, we did not use dexamethasone to prevent chronic lung disease in infants during the first 7 days of life. 16 At the discretion of the attending neonatologist, infants older than 7 days could be treated with dexamethasone to facilitate weaning from mechanical ventilation, but by 1996 this practice was reserved only for those infants with severe chronic lung disease. 16 Hence, the entire study period could be logically stratified into early (1991) (1992) (1993) (1994) (1995) and late (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) intervals based on patterns of indomethacin and dexamethasone usage. Indomethacin dosages to expectant mothers for tocolysis 8 and to infants for intraventricular hemorrhage prophylaxis were administered as described previously. 9 For effecting closure of a symptomatic PDA, indomethacin (0.1-0.2 mg/kg) was administered intravenously at 12-24 h intervals for 3-4 total doses. If indicated clinically, some infants received a second or third course of indomethacin for persistent PDA. In all infants in whom pharmacological closure could not be obtained, the PDA was ligated surgically.
Categorical data were analyzed using the w 2 -test, Fisher's exact test for 2 Â 2 tables, or the Mantel-Haenszel test. Continuous data were analyzed using the unpaired two-tailed t-test or nonparametric Wilcoxon's rank sum test as appropriate. The Breslow day test for homogeneity was used to examine the consistency of outcome event rates. Analysis of variance was used to construct interaction plots between prenatal and postnatal indomethacin exposure and its effect on neonatal gut injury. Multivariate logistic regression models were constructed to identify both perinatal and neonatal variables associated with neonatal gut injury.
Comparisons were made to identify the effects of timing of indomethacin exposure and indomethacin dosages on the risk of neonatal gut injury. Results are expressed as mean±s.d. or as odds ratio (OR) with 95% confidence intervals (CI). Significance was denoted with a P-value of <0.05. Data were analyzed using SAS 9.2 software. 17 The Institutional Review Board of the University of Florida Health Science Center at Jacksonville approved the study.
Results
Of a total 1,111 admissions to the NICU with birth weight of p1200 g, 119 were excluded from the study (Figure 1 ). The birth weight of the remaining 992 infants who comprised our study population ranged from 424 to 1200 g and gestational age from 23 to 36 weeks. Eight percent (n ¼ 79) of total 992 infants were born as small for gestational age (birth weight <10% for gestational age).
Early and late study periods There were no demographic differences between the patient populations enrolled in the early and the late study intervals. The percentage of infants exposed to antenatal betamethasone, managed with mechanical ventilation or umbilical catheters, or treated with surfactant replacement therapy, also did not change between the early and the late study intervals. A greater number of infants were born with prolonged (>24 h) rupture of membranes (5.7 vs 1.8%, P<0.005), were exposed to postnatal indomethacin (84 vs 26%, P<0.0001), and had received maternal milk feedings (62 vs 34%, P<0.0001) during the late study interval compared with infants in the early study interval. There was a reduction in the prevalence of NEC (15 vs 10%, P ¼ 0.014) and in mortality rate before discharge (26 vs 20%, P ¼ 0.025) among infants in the late compared with the early study interval. Using NEC as dependent variable, multivariate logistic regression analysis showed a negative association between indomethacin exposure and NEC (OR 0.13, CIs 0.05-0.29, P<0.0001) that was independent of maternal milk feedings. Figure 1 Flow diagram of study population, BW, birth weight, GA, gestational age at birth.
Indomethacin and neonatal gut injury R Sharma et al
Indomethacin exposure
Of all 992 study infants (Figure 1 ), 669 (67%) were exposed to indomethacin (prenatal exposure only ¼ 58, any postnatal exposure ¼ 611). Infants (323) not exposed to indomethacin did not differ from the 669 exposed infants with respect to gender ratio, ethnic background, Apgar scores, mode of delivery and use of umbilical catheters (Table 1 ). Infants exposed to indomethacin had a lower birth weight and lower gestational age at birth than unexposed infants (Table 1) . Indomethacin-exposed infants were less likely to have received late postnatal glucocorticoid (dexamethasone) before developing IIP or NEC (4 vs 8%, P ¼ 0.001) than unexposed infants. In the entire study population, only two infants had received postnatal dexamethasone before 7 days of age.
Indomethacin exposure and neonatal gut injury
The overall prevalence rate of neonatal gut injury (IIP or NEC) was 14.0% (n ¼ 139). Exposure to prenatal indomethacin alone did not increase the prevalence rate of either IIP (0 vs 0.9%, P ¼ 0.01) or of NEC (8.6 vs 14.6%, P ¼ NS, Table 2 ) compared with unexposed infants. Exposure to any postnatal indomethacin increased the prevalence rate of IIP (0.9 vs 3.8%, P ¼ 0.01) but decreased that of NEC (14.6 vs 10%, P ¼ 0.04) compared with infants without any exposure. On further inspection, the increase in IIP rate occurred in infants treated with early indomethacin to prevent intraventricular hemorrhage but not in infants who received indomethacin to effect closure of a PDA (OR 3.03, CI, 1.04-8.73, P ¼ 0.04). The first dose of early indomethacin was given at 6-12 h of age, whereas the first dose of indomethacin to effect PDA closure was administered at 3±4 days (range, 2-21 days).The adverse effect of postnatal indomethacin on IIP and the protective effect of any indomethacin exposure against NEC is illustrated in Figure 2 .
Interaction plot of prenatal and postnatal indomethacin exposure and IIP The statistical model of interaction between prenatal and postnatal indomethacin exposure vs no exposure and its effect on IIP showed that there is no interaction between prenatal and postnatal exposure as the two lines are nearly parallel ( Figure 3a ). We found that irrespective of prenatal exposure, there was an increased risk of IIP with postnatal indomethacin exposure (upward slope of both lines from no postnatal to postnatal indomethacin exposure). Table 1 Characteristics of study population exposed and unexposed to any indomethacin Interaction plot of prenatal and postnatal indomethacin exposure and NEC The interaction plot between prenatal and postnatal exposure to indomethacin vs no exposure and its association with NEC ( Figure 3b ) suggested an interaction between these two (lines in plot are not parallel). To test for such an interaction, a multiple logistic regression model was constructed using prenatal and postnatal indomethacin exposure as well as their interaction. This interaction was not significant (P ¼ 0.57). Pairwise contrasts were tested using a generalized linear model based on binomial distribution. The effect of any exposure to indomethacin vs no exposure on NEC showed a significant negative association (OR 0.64, CI 0.43-0.97, P ¼ 0.04). The prevalence of NEC for indomethacin-exposed infants was 9.9% (CI, 7.71-12.38) compared with a prevalence of 14.6% (CI 10.89-18.88) among unexposed infants. Hence, the relative risk of NEC among infants exposed to indomethacin compared with unexposed infants was 0.67 (CI 0.48-0.96). Thus, any exposure to indomethacin was associated with decreased prevalence of NEC.
Other factors
The relationship between postnatal indomethacin exposure and neonatal gut injury was not influenced by the total dosage of indomethacin. Similarly, whether feedings were continued or withheld during postnatal indomethacin administration did not modify the odds of IIP or of NEC. The odds of IIP with postnatal indomethacin exposure varied inversely with GA at birth (Figure 4 ). Using IIP as the dependent variable, a multivariate logistic regression analysis showed that a 5 min Apgar score <7, prolonged (>24 h) rupture of membranes, and postnatal exposure to indomethacin increased the odds for IIP (Table 3) whereas dexamethasone treatment did not. Among the entire study population, 61% of infants were exposed to prenatal glucocorticoid, but only two (8% of IIP) infants received early (<7days) postnatal dexamethasone before developing IIP. Twelve infants (11% of all NEC infants) received postnatal dexamethasone beyond 14 days of age before the development of NEC. 
IIP vs NEC
Characteristics of IIP infants differed from NEC infants ( Table 4) . The IIP infants were born at an earlier gestational age and experienced a longer duration of rupture of membrane before delivery than did infants who developed NEC. Onset of IIP was earlier than the onset of NEC (Table 4 ). There was a significant relationship between the last dose of indomethacin and the onset of IIP (P ¼ 0.02), but not with the onset of NEC (P ¼ NS). Eightythree percent of IIP infants manifested signs of IIP within 4 days of the last dose of indomethacin and 73% of IIP infants had received indomethacin for intraventricular hemorrhage prophylaxis before developing IIP. Sixty-four percent of infants with IIP were receiving either no or low volume (<15 ml kg -1 ) feedings at the time of onset of IIP. Conversely, 50% of infants with NEC were receiving feedings in excess of 70 ml kg -1 . The pathology of IIP was markedly different from that of NEC. These lesions were characterized by pathologists as 'isolated punched out lesions' or described by surgeons as 'cigarette burns'. Among the 26 infants with IIP, 15 infants had lesions in the ileum, six in the jejunum, three in the transverse colon, one in the ascending colon, and one in the sigmoid colon. There were nine infants with multiple lesions. In general, extensive damage to the mucosa and trans-mural ischemic hemorrhagic necrosis typical of NEC was absent. In a few cases (n ¼ 9) in which laparotomy was delayed, signs of inflammation were evident on the peritoneal (serosal) intestinal surface due to a prolonged contact (for example, failed peritoneal drain) with peritoneal fecal matter. Eleven IIP lesions were adjacent to the anti-mesenteric site.
Discussion
For several years indomethacin has been used in the treatment of refractory preterm labor 3, 4 and to affect the pharmacological closure of a PDA in neonates. 7 Despite its proven efficacy for both conditions, concern about the safety of indomethacin, particularly with respect to neonatal intestinal complications continues to influence its usage in the NICU.
5,12,13 Our investigation was designed to assess the risk of indomethacin on the two major neonatal gut injuries (IIP and NEC) that predominate the obstetrical and neonatal literature. Our prevalence study provides information that addresses several questions about the relationship between the timing of indomethacin exposure and neonatal gut injury that we believe are still incompletely answered in the current literature.
Early and late study periods Although this study spanned nearly 12.5 years, neither the population demographics nor the majority of core care practices changed between the early and the late study periods in a manner that would be expected to impact neonatal gut-injury.
Prenatal indomethacin exposure
The efficacy of indomethacin as a tocolytic has been shown in several prospective trials. 18, 19 Although some investigators have raised concerns over the possibility of increased neonatal intestinal complications, 4, 12 there are others who have not been able to support such claims. 3, 20, 21 The two cohort studies 22, 23 that showed the largest positive association between prenatal indomethacin exposure and NEC were conducted retrospectively. One study 22 found that prenatal indomethacin exposure was an independent risk factor for NEC, but these investigators assigned infants who received indomethacin for PDA closure to the unexposed group (hence masking a possible protective effect of postnatal indomethacin) and did not differentiate between NEC and IIP. The second study did not describe if any of the subjects had a PDA or had received postnatal indomethacin.
We did not identify an association between IIP and NEC and the prenatal use of indomethacin as a tocolytic. Our findings are supported by randomized trials 18, 19 and by the other two large cohort studies that investigated the efficacy of indomethacin as a tocolytic agent. [24] [25] [26] Two recent meta-analyses, 4,27 one including 21 observational studies and a second that included 28 studies (17 observational, 11 randomized clinical trials) failed to show a significant association between prenatal indomethacin exposure and either NEC or IIP. Postnatal indomethacin exposure and IIP We found that the odds of IIP were greater among infants who received early (first day) indomethacin treatment for intraventricular hemorrhage prophylaxis, but not among infants who were treated with indomethacin later in their hospital course for a PDA. Pumberger et al. 28 reported a similar experience of increased risk of IIP secondary to early postnatal indomethacin exposure. Similar to our treatment protocols, these investigators did not treat infants in the first 7 days of life with dexamethasone. Hence, in both our and in Pumberger's study, postnatal dexamethasone did not confound the risk of IIP.
Contrary to our findings, Fujii et al. 6 reported an increased incidence of NEC and NEC-associated perforation in infants treated with indomethacin for intraventricular hemorrhage prophylaxis compared with infants who received indomethacin later for PDA closure. None of these infants were reported to have developed IIP. All NEC-associated intestinal perforations were confirmed by surgical laparotomy or by autopsy. These differences could be attributed to the retrospective nature of their study, the difference in the working definition of NEC, and to the lack of a comparison group of unexposed infants. Attridge et al. 13 published a series of reports on spontaneous intestinal perforation that included an assessment of the risk of indomethacin in a retrospective analysis of a large multicenter matched cohort data set. Although these studies are in some ways similar to ours, they lack an assessment of the effect of prenatal indomethacin exposure and more importantly, not every infant with spontaneous intestinal perforation met our criteria that firmly establish a diagnosis of IIP. Therefore, it is likely that some infants who had been classified as having sustained a spontaneous intestinal perforation might have instead developed NEC. We have shown that abdominal distention, ileus and pneumoperitoneum are more common manifestations of NEC in extremely premature infants than are pneumatosis or portal venous gas. 29 Nonetheless, similar to our findings, Attridge et al. 13 did report an association between early indomethacin exposure and intestinal perforation. Unlike our study subjects, their population included infants who received dexamethasone at 0-3 days of life. Increased risk of IIP with early postnatal dexamethasone exposure with concurrent exposure to indomethacin has been found by other investigators as well. 30, 31 In our population, only two IIP infants (one with concurrent exposure to indomethacin), received dexamethasone before 7 days of age.
Postnatal indomethacin exposure and NEC Some investigators have reported an association between postnatal indomethacin treatment and NEC. 6, 14 Grosfeld et al. 14 even proposed that surgical ligation of a PDA was preferable to treatment with indomethacin to minimize the risk of NEC. Compared with the present investigation, these studies involved smaller populations and employed a retrospective analysis and a less rigorous categorization of NEC. Our finding that the risk of NEC was reduced among infants exposed to indomethacin also stands in contrast with the previous studies. Fortuitously, we were able to compare indomethacin-exposed and indomethacin-naive without a confounding effect of early postnatal dexamethasone treatment.
Several large randomized controlled trials that studied the effect of indomethacin treatment for the prophylaxis of intraventricular hemorrhage or to close PDA were unable to identify any effect of indomethacin on NEC. 9, 32, 33 Similarly, a recent population-based investigation from Israel did not find an increased risk of NEC secondary to indomethacin exposure. 34 However, these investigators did identify that a PDA was an independent risk factor for NEC. Another randomized controlled trial found that early PDA ligation in infants with birth weight <1000 g reduced the risk of NEC. 35 Our finding that the risk of NEC was lower among indomethacinexposed infants may have resulted in part because of the effects of an unidentified or less aggressively treated PDA in the indomethacin-naive group. A persistent PDA has been reported to be a risk factor for NEC by several investigators. [36] [37] [38] Mesenteric blood flow velocity is reduced in very low birth weight infants with PDA. 36, 37 Because the mucosa, by virtue of its high metabolic activity, receives about 80% of total intestinal blood flow, it is also more susceptible to critical disruption of its immune and barrier functions in the face of reductions in mesenteric and splanchnic blood flow. [39] [40] [41] Increased left-to-right shunting through a PDA can increase the vulnerability of intestinal mucosa to transient barrier dysfunction to frank ischemia. [40] [41] [42] Although indomethacin independently reduces intestinal blood flow, it appears that its net effect on intestinal blood flow when used to treat a hemodynamically symptomatic PDA is beneficial and reduces the risk of NEC. 37 The ability of indomethacin to modulate inflammatory mediators in the intestine may be another mechanism whereby it reduces the risk of NEC.
NEC vs IIP
The paradoxical effect of indomethacin on IIP and on NEC can be explained because IIP and NEC are distinct conditions with differing pathogeneses. 13, 28, 43, 44 IIP is characterized by a discrete intestinal perforation within tissue that is otherwise unaffected by inflammation or necrosis as may be seen in NEC. When present, inflammatory findings in IIP are secondary to peritoneal exposure to fecal matter. In contrast with the multifactorial pathogenesis of NEC that often has an insidious clinical onset, IIP appears to occur abruptly without systemic or local evidence of inflammation. The propensity for these focal lesions to occur in the watershed area of the terminal ileum or jejunum supports the theory of distal mesenteric arteriolar occlusion due to embolism. Arterial rectae are end arteries that supply intestinal villi. 38 Persistence of a right to left shunt through a patent foramen ovale or PDA during the critical postnatal adaptation period may predispose to arterial embolism creating IIP lesions especially when these lesions occur near the anti-mesenteric border. 16, 38 Discontinuity or defects in the intestinal muscular layer and alteration in intestinal mucosal and muscular morphology by glucocorticoids (dexamethasone) have also been implicated as contributing factors to IIP. [45] [46] [47] [48] The association between early postnatal indomethacin exposure and IIP may also have to do with the timing of exposure. One group of investigators reported negative end-diastolic flow velocity in one infant and absent end-diastolic flow velocity in seven preterm infants on day one of life. 40 Early indomethacin exposure could potentially reduce intestinal circulation during this critical transition and weaken the intestinal wall. [40] [41] [42] Subsequently, watershed areas of the gut may become susceptible to perforation with even the modest increases in intra-luminal pressure that occurs after birth. Thus, although there are gaps in our understanding of pathogenesis of IIP and of NEC, our data support that the paradoxical effects of indomethacin-exposure on IIP and NEC may be related to the timing of indomethacin-exposure and to the different nature of the two diseases.
In summary, indomethacin has a paradoxical role in neonatal gut injury. Although fetal bowel appears to be unaffected by the use of indomethacin as a tocolytic, early postnatal indomethacin exposure increases the risk of the IIP. An indomethacin-mediated reduction in postnatal intestinal blood flow during this critical period of adaptation may contribute to this effect. Conversely, late indomethacin administration to effect closure of a PDA and normalize intestinal blood flow may be protective against NEC. It is also possible that modulation of inflammatory mediators by indomethacin contributes to the observed protection against NEC. It is likely that the differential effects of indomethacin on neonatal gut injury as a function of timing of exposure are related to the different pathogeneses of IIP and NEC.
